<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02806232</url>
  </required_header>
  <id_info>
    <org_study_id>200661-0005</org_study_id>
    <nct_id>NCT02806232</nct_id>
  </id_info>
  <brief_title>An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni)</brief_title>
  <official_title>Open-label, Dose-finding, 2-parts, Efficacy Phase II Study With Three Formulations (Racemate Raziquantel Commercial Oral Tablets, New Oral Disintegrating Tablets of Racemate Praziquantel and L-praziquantel) in Schistosomiasis (S. Mansoni) Infected Children Aged 2-6 Years (Part 1), Followed by an Assessment of Efficacy and Safety With the Selected Formulation and Dosage in S. Mansoni Infected Infants Aged 3-24 Months (Part 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase II study consisting of two parts, part 1 is open label, randomized, controlled and
      exploratory dose finding in children aged between 2 and 6 years infected with S. mansoni.
      Part 2 investigates efficacy and safety with the selected formulation and dosage in S.
      mansoni infected children aged between 3 months - 2 years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2016</start_date>
  <completion_date type="Anticipated">January 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects with Clinical Cure</measure>
    <time_frame>14 to 21 days post treatment</time_frame>
    <description>Clinical cure is defined as no parasite eggs in the stools 14-21 days after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Egg Reduction Rate</measure>
    <time_frame>Baseline, 14-21 days post treatment</time_frame>
    <description>Egg reduction rate will be calculated as mean egg count per gram of stool before and after 14-21 days after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Cure</measure>
    <time_frame>14- 21 days post treatment</time_frame>
    <description>Cure defined as no evidence of parasite antigens in urine as measured with Point-of-Care Circulating Cathodic Antigen (POC-CCA) test.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Schistosomiasis</condition>
  <arm_group>
    <arm_group_label>Part 1-Biltricide (racemate praziquantel) 20 mg/kg(Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biltricide (600 mg tablet) will be administered orally at a dosage of 20 milligram per kilogram (mg/kg), three times a day as a one day treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1-Biltricide (racemate praziquantel) 40 mg/kg(Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biltricide (600 mg tablet) will be administered orally at a dosage of 40 mg/kg as a single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Racemate Praziquantel 40 mg/kg (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Racemate Praziquantel (PZQ) Oral Dispersible Tablet (ODT) (150 mg tablet) will be administered orally at a dosage of 40 mg/kg as a single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Racemate Praziquantel 60 mg/kg (Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Racemate PZQ ODT (150 mg tablet) will be administered orally at a dosage of 60 mg/kg as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Levo Praziquantel 30 mg/kg (Cohort 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levo PZQ ODT (150 mg tablet) will be administered orally at a dosage of 30 mg/kg as a single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Levo Praziquantel 45 mg/kg (Cohort 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levo PZQ ODT(150 mg tablet) will be administered orally at a dosage of 45 mg/kg as a single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Levo Praziquantel 60 mg/kg (Cohort 7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levo PZQ ODT (150 mg tablet) will be administered orally at a dosage of 60 mg/kg as a single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2- Racemate Or Levo Praziquantel (Cohort 8)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Racemate or Levo PZQ ODT will be administered orally at an optimal dose level selected by safety monitoring committee (SMC) from Part 1. Subjects aged between 13-24 months will be enrolled in this cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2- Racemate Or Levo Praziquantel (Cohort 9)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Racemate or Levo PZQ ODT will be administered orally at an optimal dose level selected by safety monitoring committee (SMC) from Part 1 and Part 2a. Subjects aged between 3-12 months will be enrolled in this cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biltricide (racemate praziquantel) oral tablets</intervention_name>
    <description>Biltricide supplied will be of 600 mg strength oral tablet. The tablets will be split in 4 if necessary to adjust the dose and then crushed, suspended in water and ingested.</description>
    <arm_group_label>Part 1-Biltricide (racemate praziquantel) 20 mg/kg(Cohort 1)</arm_group_label>
    <arm_group_label>Part 1-Biltricide (racemate praziquantel) 40 mg/kg(Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Racemate Praziquantel ODT</intervention_name>
    <description>Racemate Praziquantel (PZQ) supplied will be of 150 mg strength ODT. The tablets will be suspended in water and ingested.</description>
    <arm_group_label>Part 1 - Racemate Praziquantel 40 mg/kg (Cohort 3)</arm_group_label>
    <arm_group_label>Part 1 - Racemate Praziquantel 60 mg/kg (Cohort 4)</arm_group_label>
    <arm_group_label>Part 2- Racemate Or Levo Praziquantel (Cohort 8)</arm_group_label>
    <arm_group_label>Part 2- Racemate Or Levo Praziquantel (Cohort 9)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levo Praziquantel ODT</intervention_name>
    <description>Levo PZQ supplied will be of 150 mg strength ODT. The tablets will be suspended in water and ingested.</description>
    <arm_group_label>Part 1 - Levo Praziquantel 30 mg/kg (Cohort 5)</arm_group_label>
    <arm_group_label>Part 1 - Levo Praziquantel 45 mg/kg (Cohort 6)</arm_group_label>
    <arm_group_label>Part 1 - Levo Praziquantel 60 mg/kg (Cohort 7)</arm_group_label>
    <arm_group_label>Part 2- Racemate Or Levo Praziquantel (Cohort 8)</arm_group_label>
    <arm_group_label>Part 2- Racemate Or Levo Praziquantel (Cohort 9)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female children aged 2 to 6 years (Part 1) and 3 to 24 months (Part 2)

          -  S. mansoni positive diagnosis defined as positive egg counts in stool (greater than
             [&gt;]1 egg/1 occasion) according to World Health Organization (WHO) classification :
             light (1-99 eggs per gram of faeces), moderate (100-399 eggs per gram of faeces) and
             heavy (greater than or equal to [&gt;=]400 eggs per gram of faeces) infections

          -  Minimum weight of 8.0 kg in 2- to 6-year-old children and of 4.0 kg in 3- to 24-month
             infants

             â€¢ Parents/legal representative ability to communicate well with the Investigator, to
             understand the protocol requirements and restrictions, and willing their children to
             comply with the requirements of the entire trial, i.e.

          -  To be examined by a study physician at screening and 14-21 days after treatment

          -  To provide stool and urine samples at screening, 24 hours and 8 days after treatment,
             as well as 14-21 days after treatment

          -  To provide finger prick blood samples for Pharmacokinetics (PK) studies and blood
             samples for safety assessments

        Exclusion Criteria:

          -  Treatment in the 4 weeks prior to study screening with Praziquantel (PZQ) , other
             anti-helminthic, antimalarial or anti-retroviral compounds or any other medication
             that might affect the PK of PZQ such as certain antiepileptics (e.g., carbamazepine or
             phenytoin), glucocorticosteroids (e.g., dexamethasone), chloroquine, rifampicin or
             cimetidine

          -  For children being breast fed, treatment of the mothers/wet nurses with PZQ in the 3
             days prior to administration of Investigational medicinal product

          -  Previous history of adverse reactions associated with PZQ treatment

          -  Marked increases of the liver transaminases (alanine aminotransferase and/or aspartate
             aminotransferase) above 3x Upper Limit of Normal (ULN)

          -  History of acute or severe chronic disease including hepato-splenic schistosomiasis

          -  Fever defined as temperature above 38.0 degree centigrade

          -  Debilitating illnesses such as tuberculosis, malnutrition, etc. as well as a medical
             history of seizures

          -  Mixed S. haematobium and S. mansoni infections

          -  Findings in the clinical examination of schistosome-infected children participating in
             the study as performed by the study clinician on the treatment day, that in the
             opinion of the Investigator constitutes a risk or a contraindication for the
             participation of the subject in the study or that could interfere with the study
             objectives, conduct or evaluation

          -  Unlikelihood to comply with the protocol requirements, instructions and trial-related
             restrictions, e.g., uncooperative attitude, inability to return for follow-up visits,
             and improbability of completing the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merck KGaA Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@merckgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Merck KGaA Communication Center</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 6151 72 5200</phone>
      <email>service@merckgroup.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2016</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Praziquantel ODT formulation</keyword>
  <keyword>Biltricide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schistosomiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Praziquantel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

